Table 2.
Results | Study Sample | |||
---|---|---|---|---|
| ||||
Intent to Treat N=175 | Modified Intent to Treat N=157 | Available Data N=143 | Completers N=88 | |
Statistics | ||||
OR (95% CI) | 1.09 (0.45-2.61) | 1.06 (0.44-2.54) | 1.11 (0.46-2.65) | 1.66 (0.59-4.64) |
χ21 | 0.03 | 0.01 | 0.05 | 0.94 |
P Value | 0.855 | 0.903 | 0.823 | 0.333 |
% Neg UDS | ||||
Busprirone | 7.2% (76/1056) | 7.9% (76/960) | 12.2% (76/622) | 13.2% (70/530) |
Placebo | 6.4% (67/1044) | 7.3% (67/924) | 11.0% (67/607) | 9.9% (49/494) |
Intent to treat analysis: Analysis of all randomized participants. Modified intent to treat analysis: Analysis of ITT sample including only those that received study medication. Available data analysis: Analysis using only available, non-missing data. Completer analysis: Analysis of available data on participants who completed the week 12 study visit. Statistical results are shown from the design adjusted models.